The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...

As Modern Healthcare reports, CMS has relaxed supervision requirements for physical and occupational therapist assistants from “direct” to “general.” The change could help health systems manage ...

and Novartis. StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the ...

Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help ...

In its recent earnings release for the third quarter of 2024, Schrödinger reported significant developments, including a new collaboration with Novartis, which will see an upfront payment of $150 ...

JPM24: Caris crafts collabs with AbbVie, Flatiron to bring AI-powered genomic database to drug development That includes ...